Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/56834
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGökşin, Ş.-
dc.contributor.authorİmren, I.G.-
dc.contributor.authorKaçar, N.-
dc.date.accessioned2024-03-23T13:09:34Z-
dc.date.available2024-03-23T13:09:34Z-
dc.date.issued2024-
dc.identifier.issn21609381-
dc.identifier.urihttps://doi.org/10.5826/dpc.1401a34-
dc.identifier.urihttps://hdl.handle.net/11499/56834-
dc.description.abstractIntroduction: Many topical drugs are used in the treatment of erythematotelangiectatic rosacea ABSTRACT (ETR). However, dapsone 5% gel has never been used in ETR to date. Objectives: To evaluate the efficacy of dapsone 5% gel as a new treatment option for ETR. Methods: Thirty-five patients with ETR were included in the study. Diagnosis was made with National Rosacea Society criteria. Dapsone 5% gel was used topically twice a day for 12 weeks. Investigator Global Assessment (IGA) 4-point scale (0 → Clean, 1 → mild, 2 → moderate, 3 → severe, 4 → very severe), Visual Analogue Scale (VAS) and Dermatology Life Quality Index (DLQI) were used for evaluation (at baseline, 2nd, 6th, and 12th weeks). Results: IGA scores among baseline (2 → 62.9%, 3 → 34.3%, 4 → 2.9%) and 2nd (1 → 14.3%, 2 → 77, 1%, 3 → 8.6%), 6th (1 → 45, 7%, 2 → 54.3%) and 12th weeks (1 → 62.9%, 2 → 37.1%) were found to be statistically significant (P < 0.001). Median VAS scores among baseline (median = 7 [5-9]) and 2nd (median=5 [3-8]), 6th (median=5 [3-6]) and 12th weeks (median = 4 [2-6]) were statistically significant (P < 0.001). Median DLQI scores among baseline (median = 8 [6-14]) and 2nd (median = 5 [3-11]), 6th (median = 5 [3-11]) and 12th weeks (median = 4 [2-9]) were statistically significant (p<0.001). Concurrent systemic disease was a risk factor for poor treatment response (P = 0.034). Mild irritation was observed in 3 patients (8.5%) during treatment. Conclusions: Dapsone 5% gel was effective and well tolerated in ETR treatment. © 2024 Gökşin et al.en_US
dc.language.isoenen_US
dc.publisherMattioli 1885en_US
dc.relation.ispartofDermatology Practical and Conceptualen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectadverse eventsen_US
dc.subjectDapsone gelen_US
dc.subjecterythematotelangiectatic rosaceaen_US
dc.subjecttreatmenten_US
dc.titleEfficacy of Topical Dapsone 5% Gel for the Treatment of Erythematotelangiectatic Rosacea: New Treatment Option With Old Drugen_US
dc.typeArticleen_US
dc.identifier.volume14en_US
dc.identifier.issue1en_US
dc.departmentPamukkale Universityen_US
dc.identifier.doi10.5826/dpc.1401a34-
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.authorscopusid57194194375-
dc.authorscopusid57211810037-
dc.authorscopusid15750610300-
dc.identifier.scopus2-s2.0-85185576433en_US
dc.identifier.wosWOS:001196706800072en_US
dc.institutionauthor-
item.grantfulltextopen-
item.openairetypeArticle-
item.cerifentitytypePublications-
item.fulltextWith Fulltext-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.dept14.02. Internal Medicine-
crisitem.author.dept14.02. Internal Medicine-
Appears in Collections:Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Show simple item record



CORE Recommender

Page view(s)

36
checked on Aug 9, 2024

Download(s)

16
checked on Aug 9, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.